Medically reviewed by Dr. Pedro Martinez-Clark, MD and Dr. William O'Neill, MD. Last reviewed: July 2026.
Venezuela is an emerging clinical trial destination offering some of the lowest per-patient costs in Latin America, a 28M+ population with high disease prevalence, and an experienced investigator base. With ethics approval in 6–10 weeks via MPPS, INHRR, and SACS oversight, Venezuela is increasingly attractive for large-scale and AI-driven clinical studies.
Venezuela's clinical research ecosystem is overseen by the Ministry of Popular Power for Health (MPPS), the National Institute of Hygiene 'Rafael Rangel' (INHRR), and the Autonomous Health Contraloría Service (SACS). Together, these bodies regulate clinical investigations, biologics, and medical device studies, with ethics committee review and national authorization typically completed in 6–10 weeks.
With a population of 28M+ concentrated in Caracas, Valencia, Maracaibo, and Barquisimeto, Venezuela offers high disease prevalence across cardiovascular, metabolic, infectious, and oncology indications. Per-patient costs of $3K–$8K are among the lowest in Latin America, enabling sponsors to power larger studies, run AI/ML training cohorts, and generate real-world evidence at a fraction of US/EU costs.
bioaccess® supports sponsors entering Venezuela with ISO 14155 aligned protocols, in-country regulatory affairs, ethics committee coordination, and operational oversight across 10+ pre-qualified sites. Studies are designed with FDA submission readiness in mind under 21 CFR 812.28, including electronic data capture, structured adverse event reporting, and source data verification.
Clinical investigations in Venezuela are governed by the Ministry of Popular Power for Health (MPPS) with technical review by the INHRR (Instituto Nacional de Higiene 'Rafael Rangel') for biologics, drugs, and medical devices, and oversight by SACS for institutional compliance. Sponsors submit a protocol package including the investigator brochure, informed consent, insurance certificate, and ethics committee approval. bioaccess® manages the full submission workflow in Spanish.
Institutional ethics committees in Venezuela follow ISO 14155 E6(R2) principles and the national bioethics framework. Review timelines for first-in-human and early-phase studies average 6–10 weeks. bioaccess® works with established ethics committees at partner hospitals in Caracas, Valencia, Maracaibo, and Barquisimeto to streamline submissions and minimize cycle times.
bioaccess® has access to 10+ pre-qualified clinical trial sites across Venezuela's major medical centers. Caracas hosts the largest concentration of tertiary care hospitals and sub-specialty investigators. Valencia and Maracaibo provide strong cardiovascular, metabolic, and oncology programs. Barquisimeto adds capacity in internal medicine and infectious disease research, supporting large-scale enrollment for population-level and AI-driven studies.
The foreign clinical data is eligible for FDA submission and review from Venezuela when studies are conducted under ISO 14155 guidelines with proper ethics committee and national regulatory oversight, adequate safety monitoring, and source data verification. bioaccess® designs Venezuelan studies with FDA submission in mind, including electronic data capture, structured adverse event reporting, and audit-ready documentation.
| Metric | Venezuela 🇻🇪 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Ethics + national approval | 6–10 weeks (MPPS / INHRR / SACS) | 6–12 months (IDE + IRB) | 3–6 months (per-country CA + EC) |
| Cost per patient | $3K–$8K (among lowest in LATAM) | $40K–$75K | $35K–$60K |
| Best-fit study type | Large-scale & AI/ML training cohorts | — | — |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Time zone vs. US East Coast | Same (EST/EDT) | Same | +5 to +6 hours |
| Patient population | 28M+, high disease prevalence | 330M+ | ~450M |
Ranges reflect bioaccess® clinical studies. Actual costs and timelines vary by indication, study complexity, and monitoring requirements.
Ethics committee review in Venezuela typically takes 6–10 weeks for first-in-human and early-phase studies, running concurrently with MPPS / INHRR submission. bioaccess® coordinates directly with established ethics committees at partner hospitals in Caracas, Valencia, Maracaibo, and Barquisimeto to streamline approvals.
Per-patient costs in Venezuela range from $3,000–$8,000 depending on indication, study complexity, and monitoring requirements. These are among the lowest in Latin America, making Venezuela particularly attractive for large-scale enrollment, AI/ML training datasets, and real-world evidence studies that would be cost-prohibitive in the US or EU.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review when studies are conducted in compliance with ISO 14155, have proper ethics committee and national regulatory oversight, and include adequate safety monitoring. bioaccess® designs every Venezuelan study to FDA submission standards, including EDC, structured adverse event reporting, and source data verification.
Venezuela has experienced investigators and high disease prevalence in cardiovascular, metabolic (diabetes, obesity), infectious disease, oncology, and internal medicine. The population scale and concentration in Caracas, Valencia, Maracaibo, and Barquisimeto make it particularly well-suited for large-scale studies and AI/ML model training requiring diverse, real-world datasets.
bioaccess® applies the same ISO 14155 standards used across all LATAM markets: pre-qualified investigators, ethics committee oversight, insurance coverage, structured adverse event reporting, on-site monitoring, and source data verification. All sites are vetted for infrastructure, staff training, and regulatory compliance before activation.
Yes. bioaccess® handles regulatory submissions to MPPS / INHRR / SACS, ethics committee coordination, site selection and activation, contracting, monitoring, and data management. Sponsors get a single point of accountability for the entire program, with bilingual project leadership and FDA-submissible deliverables.
All countries we serve · Contact bioaccess® · First-in-Human CRO